Wednesday, September 3, 2025

Latest

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.

Dr. Theriault outlines Cytophage’s expansion strategy, focusing on South Asia with a new product launch in Bangladesh and partnerships with major poultry integrators. He also touches on the development of phage-based vaccines and the company’s focus on both animal and human applications.

Looking ahead, Dr. Theriault highlights Cytophage’s goals: revenue generation, advancement of human clinical trials, and formation of strategic partnerships. These reflect the company’s ambition to capitalize on the growing interest in phage therapy.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Cormark Lifts Northern Superior Target To $2.00 On Drilling Success

Afghanistan Quake Deaths Pass 1,400

Related News

Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba

Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment...
Thursday, December 12, 2024, 05:14:00 PM

McDonald’s E.coli Crisis: This Canadian Biotech May Have The Solution | Cytophage with Steven Theriault

In this interview, Dr. Steven Theriault, CEO & Chief Science Officer of Cytophage Technologies (TSXV:...
Saturday, November 16, 2024, 09:13:00 AM

Cytophage: Landmark Phage Therapy Saves Ottawa Woman From Life-Threatening Infection

A 79-year-old resident from the Ottawa area credits an experimental treatment developed in Winnipeg with...
Wednesday, April 3, 2024, 07:56:00 AM

Cytophage Launches Trials For OvaPhage Under Hatchery Partnership

Cytophage Technologies (TSXV: CYTO) has officially launched trials with one of the largest poultry hatcheries...
Thursday, February 6, 2025, 07:29:00 AM

Cytophage To Focus On Commercialization Efforts In 2024

Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a...
Tuesday, April 30, 2024, 10:13:02 AM